Published in World J Surg Oncol on June 24, 2016
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer (2000) 2.07
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res (2012) 1.85
Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol (2002) 1.71
Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer (2012) 1.01
CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract. Cancer (1986) 1.00
Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol (1996) 1.00
Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol (2012) 0.98
Combination therapy of albumin-bound Paclitaxel and Carboplatin as first line therapy in a patient with ovarian cancer. Case Rep Oncol Med (2014) 0.83
[Analysis of risk factors for epithelial ovarian cancer recurrence]. Ai Zheng (2003) 0.81
Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification. J Ovarian Res (2015) 0.81
Which one among the Pt-containing anticancer drugs more easily forms monoadducts with G and A DNA bases? A comparative study among oxaliplatin, nedaplatin, and carboplatin. Inorg Chem (2011) 0.80
[Combination chemotherapy of paclitaxel followed by nedaplatin for human ovarian cancer]. Gan To Kagaku Ryoho (2002) 0.80